Whole genome sequencing reveals genetic signature of bedaquiline resistance in a clinical isolate of Mycobacterium tuberculosis.

Related Articles

Whole genome sequencing reveals genetic signature of bedaquiline resistance in a clinical isolate of Mycobacterium tuberculosis.

J Glob Antimicrob Resist. 2018 Sep 21;:

Authors: Chawla K, Martinez E, Kumar A, Shenoy VP, Sintchenko V

Abstract
OBJECTIVES: Emergence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) strains have opened new challenges for tuberculosis control in India. This study examined molecular markers of resistance to bedaquiline, a new antituberculous drug with a potential to dramatically improve MDR-TB treatment outcomes and reduce mortality.
METHODS: A clinical isolate of Mycobacterium tuberculosis with MDR-TB profile was subjected to genome sequencing using Illumina NextSeq500 platform followed by a genome wide-analysis.
RESULTS: A mutation on Rv0678 coding region associated with in vitro bedaquiline resistance was identified. The strain represented Delhi/CAS lineage.
CONCLUSIONS: This first report of potentially bedaquiline resistant strain in India highlights the role of genome-wide sequence analysis of isolates from tuberculosis cases with a history of treatment in countries with high burden of MDR- and XDR-TB.

PMID: 30248414 [PubMed - as supplied by publisher]